Flow‐Induced Vascular Remodeling on‐Chip: Implications for Anti‐VEGF Therapy
Flow‐induced vascular remodeling plays a critical role in network stabilization and function. Using a vasculature‐on‐chip system, this study reveals how physiological VEGF levels and flow affect vascular remodeling and provides insights into tumor vessel normalization.
Fatemeh Mirzapour‐Shafiyi+6 more
wiley +1 more source
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL [PDF]
Uy, Geoffrey L.
core +1 more source
Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as induction chemotherapy regimen for hypopharyngeal cancer. [PDF]
Jiang C+11 more
europepmc +1 more source
A 3D bioprinted HNSCC model for use in anti‐cancer drug testing is established in proof‐of‐concept. The innovative tunicate‐derived nanocellulose hydrogel proved to be a viable alternative to gelatin‐based hydrogel, offering improved bioprintability for HNSCC model establishment.
Alexya Azhakesan+7 more
wiley +1 more source
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck [PDF]
Roy B. Tishler+11 more
openalex +1 more source
Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced head and neck squamous cell carcinoma: A real-world data study. [PDF]
Perin MY+8 more
europepmc +1 more source
VATS Pneumonectomy After Induction Chemotherapy [PDF]
openaire +1 more source
Schematic illustration of the mechanism of targeted delivery of nanoparticles including 1) paracellular, 2) endolysosomal escape, 3) receptor mediated endocytosis, and 4) M cell mediated transport for non‐GI diseases by oral administration such as atherosclerosis, cancer, diabetes, and brain diseases. Abstract Oral drug delivery is a promising approach
Subarna Ray+2 more
wiley +1 more source
Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy. [PDF]
Abi Frem J+6 more
europepmc +1 more source